ASCO Senior Vice President and Chief Medical Officer, Richard L. Schilsky, MD, FACP, FASCO, FSCT, will participate in a panel discussion at ECRI Institute’s 24th Annual Conference on workarounds in clinical care on November 28-29, at Georgetown University.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
Registration is open for the QOPI® Fall Round. The QOPI® Fall Round ends Tuesday, Nov. 7, 2017, at 5 p.m. (ET).
On Tuesday, Sept. 26, the United States Senate announced it would not vote on H.R. 1628, the Graham-Cassidy-Heller-Johnson Amendment to the American Health Care Act, which would have repealed the Affordable Care Act (ACA) and moved the law’s funding into block grants for states.
On October 3, 2017, the Food and Drug Administration announced updates to three final guidance documents, including Form FDA 3926 and its instructions, to simplify Institutional Review Board (IRB) review requirements for physicians seeking to treat an individual patient with an investigational drug under expanded access. The updates allow for a waiver of the requirement for review and approval at a convened IRB meeting if the physician instead obtains concurrence by the IRB chairperson (or a designated IRB member) before treatment use begins.
On October 3, the Centers for Medicare & Medicaid Services (CMS) officially withdrew the proposed Medicare Part B Drug Demo, which would have reduced the Average Sales Price (ASP) reimbursement rate for Part B drugs based on primary care service areas. ASCO has opposed the demo since its release in March 2016, citing a flawed premise, experimental nature, and lack of important patient protections. The proposal stalled in late 2016, but was never formally withdrawn.
On September 29, the U.S. Pharmacopeial Convention (USP) announced it will postpone the official date of General Chapter 800, “Hazardous Drugs – Handling in Healthcare Settings,” (USP 800) to Dec. 1, 2019.
The ASCO Research Community Forum (RCF) Annual Meeting — a unique event that brings together researchers and staff from cancer research sites across the country to discuss challenges and identify best practices in conducting and managing clinical trials — was held September 24-25.
ASCO recently joined nearly two dozen advocacy groups, representing millions of patients with serious and life-threatening diseases, in sending a letter to House Energy and Commerce Committee leadership strongly opposing “right-to-try” (RTT) legislation currently under consideration. The letter urges the committee to instead work on policies that would safely increase access to promising investigational therapies for patients.
ASCO and Friends of Cancer Research (Friends) are calling for the use of more inclusive eligibility criteria for cancer clinical trials. This recommendation is in conjunction with the release of a Special Series, published today in the Journal of Clinical Oncology (JCO). The series, which includes a joint ASCO-Friends research statement, provides a comprehensive examination of eligibility criteria for cancer clinical trials with recommendations to address eligibility criteria in five specific areas: minimum age requirements for trial enrollment, HIV/AIDS status, brain metastases, organ dysfunction, and prior and concurrent malignancies.
Close to 100 ASCO volunteers from across the country came to Capitol Hill on September 27-28 for the second Annual ASCO Advocacy Summit, where they urged Congress to act on major policy priorities to improve research and access to treatment for the more than 15.5 million people in the United States living with a history of cancer.
ASCO volunteers asked members of Congress to:
On September 28, 2017, the Food and Drug Administration approved abemaciclib (VERZENIO™, Eli Lilly and Company) in combination with fulvestrant for women with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. In addition, abemaciclib was approved as monotherapy for women and men with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.
After serving for 10-years as Editor-in-Chief for Journal of Oncology Practice (JOP), John V. Cox, DO, FASCO’s term will officially conclude on December 31, 2018. Dr. Cox’s term marks a period of tremendous growth for the journal and has included expanded content, monthly print publication, and growing recognition with a wide audience in the oncology field.
Members of Congress urged leaders of the House of Representatives to invest in medical research and protect funding for the National Institutes of Health (NIH), including facilities and administration (F&A) costs.
The American Society of Clinical Oncology (ASCO) today presented Representative Leonard Lance (NJ-7) with its second annual Congressional Leadership Award in recognition of the lawmaker's exceptional commitment to supporting cancer research and treatment. The ASCO award honors a member of Congress who is a leading champion for patients and survivors of cancer, their families, and their cancer care teams.